English
  • Laroprovstat

    Laroprovstat

    API’s Name CAS No. US DMF Patent Expiry Date( U.S) Current Status 
    Laroprovstat 2455427-91-3  2027 Jan.23, 2040

     

    [Indication] 

    1. Hypercholesterolemia: For the reduction of low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolemia, as an adjunct to statin therapy.

    2. Dyslipidemia: For the management of dyslipidemia in adult patients.

    3. Cardiovascular Disease: For the reduction of cardiovascular risk in patients with atherosclerotic cardiovascular disease (ASCVD).

    inquirydetail
  • Ledipasvir Acetone

    Ledipasvir Acetone

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
    Ledipasvir Actone 1441674-54-9  ✓   Nov.12, 2030

     

    [Indication] 

    Ledipasvir and sofosbuvir is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older:

    1. Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.

    2. Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.

    3. Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.

    inquirydetail
  • LCZ696 (Sacubitril + Valsartan)

    LCZ696 (Sacubitril + Valsartan)

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    LCZ696 (Sacubitril + Valsartan) 936623-90-4 35480  May.27, 2027 Commercial Production

     

    [Indication]

    For the treatment of patients with chronic heart failure to reduce the risk of cardiovascular death and hospitalization for heart failure.

    inquirydetail
  • Lenalidomide

    Lenalidomide

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Lenalidomide 191732-72-6 31804 Commercial Production

     

    [Indication]

    1. In combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma, or for patients who have received at least one prior therapy.

    2. For the treatment of transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (MDS) with deletion 5q cytogenetic abnormality.

    3. For the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

    inquirydetail